The melanocortin system comprises five G-protein-coupled receptors (MC1R through MC5R) and a small family of endogenous ligands derived from POMC (pro-opiomelanocortin). The three compounds in this category are synthetic analogs of that system, and what separates them is receptor selectivity.
Non-selective vs. MC4R-selective
Melanotan I is the original linear tridecapeptide analog of alpha-MSH. Melanotan II is a smaller, cyclic, more receptor-potent analog developed afterward — but both are non-selective agonists across the melanocortin receptor family, meaning they activate MC1R (found on melanocytes and immune cells) alongside MC3R/MC4R (concentrated in the central nervous system, tied to appetite and other centrally mediated circuits) more or less indiscriminately. PT-141 (bremelanotide) was developed specifically to narrow that profile: it's engineered to be substantially more MC4R-selective than either Melanotan compound.
Why selectivity is the variable that matters here
Because MC1R and MC4R sit in very different physiological systems, a non-selective agonist produces effects at both sites simultaneously. In animal models, this shows up as pigmentation changes occurring alongside cardiovascular and other centrally mediated signals — effects a more selective compound like bremelanotide is specifically designed to reduce by concentrating activity at MC4R. This is the central reason researchers distinguish "melanocortin agonist" from "MC4R-selective agonist" rather than treating the three compounds as interchangeable.
| Receptor | Distribution | Peptides in this category |
|---|---|---|
| MC1R | Melanocytes, immune cells | Melanotan I, Melanotan II (non-selective) |
| MC3R / MC4R | CNS — appetite and centrally mediated signaling | Melanotan II (non-selective), PT-141/bremelanotide (MC4R-selective) |
| MC2R, MC5R | Adrenal cortex; exocrine glands, skeletal muscle | Not targeted by compounds in this catalog |
Where these compounds originated
Melanotan I began as tanning research at the University of Arizona, developed to study UV-independent pigmentation as a strategy against skin cancer. Melanotan II followed as a more potent, cyclic derivative from the same research program. PT-141 has a different origin: it emerged from that same melanocortin drug-discovery effort after researchers observed an unrelated effect during early studies and later isolated and optimized the underlying MC4R-mediated pathway independently of the pigmentation research that produced the two Melanotan compounds. The three peptides share a chemical ancestor but were developed toward distinct research endpoints from there.
As with other lyophilized research peptides, melanocortin analogs are typically reconstituted with sterile bacteriostatic water and kept refrigerated once in solution; batch-specific handling and analytical data are on each product page.
